![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
Preview |
PDF (Supplementary Material)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
459kB |
| Item Type: | Article |
|---|---|
| Title: | Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia |
| Creators Name: | Becker, H., Pfeifer, D., Ihorst, G., Pantic, M., Wehrle, J., Rüter, B.H., Bullinger, L., Hackanson, B., Germing, U., Kuendgen, A., Platzbecker, U., Döhner, K., Ganser, A., Hagemeijer, A., Wijermans, P.W., Döhner, H., Duyster, J. and Lübbert, M. |
| Abstract: | TP53 aberrations reportedly predict favorable responses to decitabine (DAC) in acute myeloid leukemia (AML). We evaluated clinical features and outcomes associated with chromosome 17p loss or TP53 gene mutations in older, unfit DAC-treated AML patients in a phase II trial. Of 178 patients, 25 had loss of 17p in metaphase cytogenetics; 24 of these had a complex (CK+) and 21 a monosomal karyotype (MK+). In analyses in all patients and restricted to CK+ and MK+ patients, 17p loss tended to associate with higher rates of complete remission (CR), partial remission (PR), or antileukemic effect (ALE). Despite favorable response rates, there was no significant OS difference between patients with or without loss of 17p in the entire cohort or in the CK+ and MK+ cohort. TP53 mutations were identified in eight of 45 patients with material available. Five of the eight TP53-mutated patients had 17p loss. TP53-mutated patients had similar rates of CR/PR/ALE but shorter OS than those with TP53 wild type (P = 0.036). Moreover, patients with a subclone based on mutation data had shorter OS than those without (P = 0.05); only one patient with TP53-mutated AML had a subclone. In conclusion, 17p loss conferred a favorable impact on response rates, even among CK+ and MK+ patients that however could not be maintained. The effect of TP53 mutations appeared to be different; however, patient numbers were low. Future research needs to further dissect the impact of the various TP53 aberrations in HMA-based combination therapies. The limited duration of favorable responses to HMA treatment in adverse-risk genetics AML should prompt physicians to advance allografting for eligible patients in a timely fashion. |
| Keywords: | Decitabine, Acute Myeloid Leukemia, AML, Mutations, TP53, Monosomy |
| Source: | Annals of Hematology |
| ISSN: | 0939-5555 |
| Publisher: | Springer |
| Volume: | 99 |
| Number: | 7 |
| Page Range: | 1551-1560 |
| Date: | July 2020 |
| Official Publication: | https://doi.org/10.1007/s00277-020-04082-7 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
